Soligenix Entered into an Exclusive Option Agreement with Silk Road Therapeutics to Acquire Pentoxifylline for Behçet's Disease
Shots:
- Soligenix gets the right to acquire a novel topical formulation of Pentoxifylline (non-biological anti-TNF-alpha inhibitor) for the treatment of mucocutaneous ulcers in patients with Behçet's Disease (BD)
- In the P-II POC study, the results showed an accelerated oral ulcer healing and decreased pain over SoC in patients with BD & was found to be superior to colchicine, patients had index ulcer area shrinkage by Day 2 & undetectable index mouth ulcer by Day 4 (83% & 72% vs 19% vs 29%), pain scores were also found to decrease, no serious AEs were seen & consistent with the systemic use of PTX in the published literature
- PTX received ODD & FTD from the US FDA & was being developed under a 505(b)(2) accelerated regulatory pathway in the US
Ref: Soligenix | Image: Soligenix
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
